GSK & Cambridge Develop Drugs for Disease

News Medical has reported that a new collaboration between the University of Cambridge and GSK will aim to discover and develop new medicines to treat liver disease.

The collaboration with GSK will combine Professor Lomas’ long-term research at the University of Cambridge Institute for Medical Research (CIMR) with GSK’s expertise in drug discovery and development in order to develop new therapeutics. Work on the project will be carried out both at GSK and at the CIMR.

This new partnership will build upon the work of researchers who have identified a molecular mechanism that plays a major role in the life-threatening liver disease that develops in patients with a particular mutant gene.

Alpha-1 antitrypsin (A1AT) deficiency is one of the most common genetic disorders in the UK, affecting approximately one in 2,000 people. Professor Lomas said that “Currently, the only option for patients with liver disease as a result of alpha-1 antitrypsin deficiency is transplantation…….This partnership brings together our collective expertise in target biology and drug discovery to tackle an unmet medical need and by teaming up with GSK, we have a great opportunity to turn our research into effective treatments”

 

Are you looking for a new position in the pharmaceutical industry?

Click here to search our pharmaceutical jobs online now.

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , , , , , , , , ,

Icon Plc partnership with College Dublin

Pharmatimes have reported that Icon plc have joined a strategic alliance with the University College Dublin to advance research

Icon have said that this new partnership supports a shared vision for transforming research, teaching, training and innovation in the sciences in Ireland and aims to strengthen the ties between academic research and industry.

Icon have established the ICON Newman Fellowship in Genomics as one component of the partnership. This will be a two-year post-doctoral fellowship based at the UCD School of Medicine and Medical Science and at the College’s Complex and Adaptive Systems

Also ICON and the University College Dublin will work collaboratively on ways to enhance drug development.

The partners said that “This programme has “the potential to include tailored teaching programmes and internships in clinical research that will be available in Ireland and internationally through some of UCD’s university partners”,

 

Are you looking for a new position in the pharmaceutical industry?

Click here to search our pharmaceutical jobs online now.

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Ironwood’s drug for IBS sufferers gets FDA approval

Fierce Pharma have reported that Ironwood Pharmaceuticals Inc.  and Forest Laboratories Inc.  won regulatory approval of their Linaclotide treatment for irritable bowel syndrome with constipation.

Linaclotide has shown in studies to help alleviate abdominal pain and symptoms of constipation. Ironwood has said that as many as 11 million Americans have irritable bowel syndrome with constipation, and for many it comes with a lot of pain. While Takeda Pharmaceutical is already in the market with its Amitiza, analysts say the fact

that the Ironwood drug may relieve pain will help it quickly outsell its competition.

Linaclotide was developed by Ironwood with New York-based Forest Labs, and the companies will co-promote the drug in the U.S. Ironwood licensed the drug in Europe to Barcelona, Spain- based Almirall SA (ALM), and to Tokyo-based Astellas Pharma Inc. (4503) for several Asian countries.

Looking for a new job in the pharmaceutical sector? Start by clicking here

Posted in Industry NewsTagged in , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Alliance Pharma Expands Into Europe

Alliance Pharma have made a positive move into the European market after purchasing three drugs brands from AstraZeneca, reports proactiveinvestors.co.uk.

The drugs, all three of which are anti-malarial, were bought for just over £4 million and will bring Alliance “into new territories and mark [their] first significant steps onto the continent” says Finance Director Richard Wright. Alliance may have to pay a further £1 million dependant on sales of the drugs.

Alliance have also added significant experience in the appointment of new country managers for France and central Europe. Chief Executive John Dawson has said “We are delighted to add these important anti-malarial brands to the Alliance portfolio,” before expressing his delight at the addition of experience to spearhead Alliance’s European expansion.

Looking for a job in the pharmaceutical sector? Start by looking here

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , ,

AstraZeneca and 4 research labs form the A5 Alliance to collaborate on Alzheimer’s disease

Reuters have reported that AstraZeneca and Dr. Steven Paul of Weill Cornell Medical College today announced a first of its kind research collaboration that brings four leading academic research laboratories together with AstraZeneca to work on the disease Alzheimer’s

This new alliance will be called the A5 alliance, the members represent a team of academic scientists with expertise in ApoE biology who will focus on identification, validation, and risk reduction of drug targets for treatment of Alzheimer’s disease.

The A5 Alliance will study a major risk factor for Alzheimer’s disease, the apolipoprotein E4 genotype (ApoE). ApoE is considered second only to age as a risk factor for the development of Alzheimer’s disease. Under the terms of the A5 alliance, AstraZeneca will fund the academic research and members of AstraZeneca’s Neuroscience Innovative Medicines unit will contribute programme management and scientific expertise. The academic alliance members will contribute their disease area knowledge and expertise, as well as lead specific aspects of the research programme in their laboratories.

 

Are you looking for a new role in the pharmaceutical industry?

Click here to see our latest pharmaceutical roles

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Biogen and Isis Team Together in Rare Disease Pact

PharmaTimes reported that Biogen Idec and Isis Pharmaceuticals are forming a partnership to develop an antisense drug for muscular dystrophy in adults (DM1)

Muscular Dystrophy is estimated to affect 150,000 patients in the USA, Europe and Japan and is passed from parent to child with each subsequent generation experiencing more severe disease earlier in life.

Isis will be responsible for the discovery of a lead antisense drug candidate targeting DMPK for the treatment of DM1 (muscular dystrophy in adults)

Steven Holtzman, head of corporate development at Biogen said that “the unmet need is great and there are currently no therapies to slow or stop progression of the disease” He also said DM1 has “an identifiable genetic cause, the program fits with our mission to bring innovative therapies to patients with serious neurologic diseases, and Isis’ antisense compound has the potential to make a real difference”

 

Are you looking for a new clinical job? Click here to see our latest clinical jobs

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

 

 

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , , ,

CK Clinical Celebrate the Opening of London Office

CK Clinical, is today celebrating the opening of our new London office. With an already thriving office based in Stevenage Hertfordshire, our new London office will be the hub of our expanding recruitment operations across Europe.

This is an extremely exciting time for CK, as Priya Priya Mukherjee, European Operations Manager explains, “I am delighted to be part of the new European expansion and looking forward to taking CK Clinical to new heights across the European Pharmaceutical market.

Being based at our new central London location means we have easy access to London City Airport and Heathrow, enabling us to continue the great service we offer and meet our clients and candidates when required. We are all looking forward to the coming months and settling into our new place of work.”

 

The new London office will be home to a number of CK Clinical’s specialist Clinical Recruitment Consultants including:

 

  • Priya Mukherjee - European Operations Manager at CK ClinicalPriya Mukherjee, European Operations Manager

Priya is heading up CK Clinical’s European recruitment operations and will also be focusing on Biometrics recruitment across Europe.

 

 

 

 

 

  • Moin Din - Senior Recruitment Consultant at CK ClinicalMoin Din, Senior Recruitment Consultant

Moin specialises in recruiting medically qualified professionals within the pharmaceutical industry across the UK and Europe.

 

 

 

 

 

  • Mylene Paumier - Consultant at CK ClinicalMylene Paumier, Recruitment Consultant

Mylene specialises in recruiting for Biometrics professionals within the pharmaceutical industry across the UK and Europe.

 

 

 

 

 

  • Hendre Moolman - Senior Consultant at CK ClinicalHendre Moolman, Senior Recruitment Consultant

Hendre Moolman specialises in recruiting for Pharmacovigilance, Drug Safety, Medical Information and Medical Affairs professionals within the pharmaceutical industry across the UK and Europe.

 

 

 

The address of CK Clinical’s new London office is as follows:

CK Clinical London Office in HammersmithCrown House

72 Hammersmith Road

Hammersmith

London

W14 8TH

Tel: +44 (0)207 470 5670

 

Posted in General, NewsTagged in , , , , , , , , , , , , , , , , , , , , , ,

Senior Programmer – Cambridge

Mylene Paumier is recruiting for a Senior Programmer to join a global pharmaceutical company at their site based in Cambridge on a 6months contract basis.

The job:

As a Senior Programmer you will be involved in data manipulation, analysis and reporting of primarily clinical trial data. You will have responsibility for:

  • Analysis files creation
  • Table/listing/graph generation
  • Program validation and documentation
  • Output verification
  • Work is to be performed in a team environment, where team members may be distributed across locations and Suppliers.

Qualifications:

As Senior Programmer, you will have the following qualifications, skills and experience:

  • BA/BSc or higher degree in Computer Science, Statistics, Mathematics, Life Sciences or other related scientific subject, or work experience equivalent
  • Specialist relevant programming experience in a clinical development environment
  • Excellent SAS data manipulation, analysis and reporting skills
  • Familiarity with drug development life cycle and experience with the manipulation, analysis and reporting of clinical trials data
  • Ability to work effectively and successfully in a team environment
  • Excellent oral and written communication skills
  • Ability to provide quality output and deliverables, in adherence with challenging timelines
  • Willingness and ability to learn and follow standard processes and procedures.

Mylene Paumier - Recruitment Consultant at CK ClinicalHow to apply:

Apply online:

For more information or to apply for this Senior Programmer position, please contact Mylene Paumier on 01438 743047 or email: mpaumier@ckclinical.co.uk. Please quote reference CL24558 in all correspondence.

Looking for a job in the Pharmaceutical Industry?Click here to search our pharmaceutical jobs online now.

Posted in Featured Jobs, NewsTagged in , , , , , , , , , , , , , , , , , , , , , ,

AstraZeneca to develop asthma treatment

As reported by PharmaTimes, AstraZeneca has signed an exclusive global licence deal with USA-based Rigel Pharmaceuticals for a potential new treatment for chronic asthma.

The drugs is Rigels R256, it is being investigated as a treatment for moderate to severe chronic asthma and in preclinical research has been shown to reduce airway inflammation and improve lung function.

AstraZeneca will be responsible for beginning first-in-human clinical studies for R256 and have exclusive rights to commercialise the drug around the world.  Rigel will receive an upfront fee of $1 million with an additional $8.25 million in early milestone payments. In total, the deal could be worth up to $100 million.

Mene Pangalos, head of innovative medicines at AstraZeneca, said “there remains a need for more targeted therapies for moderate to severe chronic asthma”.

Looking for a job in the Pharmaceutical Industry?Click here to search our pharmaceutical jobs online now.

Posted in company news, NewsTagged in , , , , , , , , , , , , , , , , , ,

Advances in medicine helps a 10 year old girl

BBC News has reported that a 10-year-old girl has had a major blood vessel in her body replaced with one grown with her own stem cells according to Swedish doctors

A team led by Professor Suchitra Sumitran-Holdgersson of the University of Gothenburg successfully transplanted a vein made from a 10-year-old girl’s own stem cells into her body.  It is the first time such an operation has been reported and marks an important step in the practical ability of doctors to use stem cells to grow replacement cells for damaged or diseased tissue.

Professors Martin Birchall and George Hamilton, from University College London, said: “The young girl was spared the trauma of having veins harvested from the deep neck or leg with the associated risk of lower limb disorders. Birchall and Hamilton also said the procedure may get cheaper as medical companies start producing protein scaffolds from human and animal sources more efficiently. They concluded that Prof Sumitran-Holdgersson’s work was promising, but it needed to be properly tested in full clinical trials if such regenerative medicine treatments were to become widely used and accepted.

Are you looking for a new clinical job? Click here to see our latest clinical jobs

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , , ,